Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Opioid Use Disorder Clinical Trial

Official title:

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05027919
• Other study ID #: IRB00279895
• Secondary ID: 1R01DA052937
• Status: Recruiting
• Phase: Phase 2
• Start date: February 1, 2022
• Est. completion date: February 28, 2026

Study information

• Verified date: February 2024
• Source: Johns Hopkins University
• Contact: Kelly E Dunn, Ph.D, M.B.A.
• Phone: 410-550-2254
• Email: kdunn9[@]jhmi.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.

Description:

Individuals who have opioid use disorder and are interested in being tapered off of opioids will be admitted to a residential research unit for an 11-day period. All participants will be maintained on morphine for 5 days. During this period participants will complete 2 sessions (on two different days) wherein participants will receive an intramuscular injection of naloxone to precipitate a short withdrawal syndrome. Participants will take a capsule prior to both sessions that will contain either placebo or the opioid withdrawal medication lofexidine. Beginning on day 6 participants will be tapered off of morphine using lofexidine (as clinically indicated). At the end of the study all participants will be able to transition to buprenorphine maintenance or receive oral naltrexone and an injection of Vivitrol (extended release naltrexone), consistent with standard of care practices. Investigators will collect a variety of biological samples and questionnaire ratings during the study and primary outcomes will be measures of withdrawal collected throughout the study. Investigators will use these data to learn more about why individuals express opioid withdrawal symptoms differently, which will help inform how to change current treatment practices to be more effective for persons with OUD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: February 28, 2026
• Est. primary completion date: November 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 18 years - 65 year old

• Opioid-positive urine sample

• Current opioid use disorder with evidence of physical dependence

• Interest in undergoing opioid taper

Exclusion Criteria:

• Evidence of physical dependence on alcohol or benzodiazepines that requires medical intervention

• Being pregnant or breastfeeding

• Enrolled in methadone or buprenorphine maintenance treatment

• Clinically significant hypotension (<90/60mmHg) or bradycardia (<45bpm)

• History of myocardial infarction

• Subjects who are positive for hepatitis B surface antigen and/or hepatitis C antibody with liver function tests outside the normal range (persons with a positive hepatitis C antibody and normal liver functions tests are NOT excluded from the study)

• Significant mental health or physical disorder, or life circumstances, that is expected to interfere with study participation

Related Conditions & MeSH terms

• Opioid Craving
• Opioid Use Disorder
• Opioid Withdrawal
• Opioid-Related Disorders
• Substance Withdrawal Syndrome

Intervention

Drug:
• Morphine
30mg subcutaneous injections of morphine 4 times daily on days 1 through 5.
• Naloxone + lofexidine pretreatment
0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
• Naloxone + placebo pretreatment
0.4mg naloxone injection during the Naloxone challenge
• Lofexidine
Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.

Locations

Country	Name	City	State
United States	Johns Hopkins University Bayview Medical Campus	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Withdrawal severity during lofexidine taper	Withdrawal severity as assessed by the Subjective Opioid Withdrawal Scale. (The score range is 0 through 64) with higher score indicating more severe withdrawal.	Days 6 through 10
Primary	Withdrawal severity during naloxone challenge	Withdrawal severity as assessed by the Subjective Opioid Withdrawal scale scores (The range is 0 through 64) with higher score indicating more severe withdrawal. Collected during two naloxone challenges (pretreatment with lofexidine and pretreatment with placebo).	Days 1 through 5